Kinetic Patterns of Antibiotic Consumption in German Acute Care Hospitals from 2017 to 2023

Antibiotics, Journal Year: 2025, Volume and Issue: 14(3), P. 316 - 316

Published: March 18, 2025

Background: Antimicrobial consumption (AMC) patterns, besides prescribing behaviors, reflect the changing epidemiology of infectious diseases. Routine surveillance data have been used to investigate development AMC from 2017 2023 and impact COVID-19 within context framing time periods. Methods: Data 112 hospitals, continuously participating in national system hospital antimicrobial based at Robert Koch Institute, were analyzed according WHO ATC (Anatomical Therapeutic Chemical)/DDD (Defined Daily Dose) method categorized AWaRe-classification. was quantified by density (CD) expressed DDD/100 patient days (PD) admissions (AD). The period subdivided into three phases: pre-pandemic phase (2017–2019), main pandemic (2020–2021) transition (2022–2023). Linear regression models determine presence an overall trend, change intra-phasic trends phase-specific mean levels over time. Results: From total antibiotic decreased 7% 57.1 52.9 PD. Four kinetic patterns emerged across different classes: Pattern 1 displays a decreasing which slowed down throughout exhibited second-generation cephalosporins fluoroquinolones. 2 reveals rising decelerated accelerated again aminopenicillins/beta-lactamase inhibitors, beta-lactamase sensitive pencillins, azithromycin first-generation cephalosporins. 3 shows elevated carbapenems, glycopeptides, linezolid third-generation 4 trend phase, reversed without achieving resistant penicillins, daptomycin, fosfomycin (parenteral) ceftazidime/avibactam. Conclusions: Kinetic classes might COVID-19-related effects associated changes co-circulating pathogens health care supply. Broad-spectrum antibiotics with persisting require special attention focused stewardship activities.

Language: Английский

Impact of the COVID-19 Pandemic on Inpatient Antibiotic and Antifungal Drug Prescribing Volumes in Germany

Published: Aug. 12, 2024

Background: Previous studies have found variable impact of the coronavirus disease 2019 (COVID-19) pandem-ic on consumption antimicrobial drugs in human medicine, with trends several European countries differing between community and inpatient prescribing. Aim: This study analysed changes volumes use density antibacterial antifungal dis-pensed acute care hospitals Germany 2022. Methods: Surveillance data for four years available from 279 hospitals, among them 272 antifungals, were expressed as total daily doses or (daily per 100 patient/occupied bed days) year descriptively, using recommended hospital-adapted dose definitions (RDD) (as sensitivity analysis) WHO/ATC-defined (DDD). Hospitals stratified according to size (number beds) university affiliation, location (East, West, South). Results: There significant decreases both number patient days drug vol-umes 2020 through 2022 compared 2019. The relative 2020, 2021 -12.8%, -13.5%, -13.3% days, -9.7%, -11.0%, -10.1% RDD, respec-tively. Broad-spectrum betalactams, notably piperacillin-tazobactam carbapenems, increased volume unlike most other classes. resulting was slightly but significantly increas-ing pooled means (and medians) 43.3 (40.0) RDD/100 44.8 (41.7), 44.5 (40.80), 44.9 (41.7) 2022, respectively. Antifungal after peaked (differences +6.4%, mean values +22.9%, respectively). These similar different hospital strata comparable when DDD instead RDD used. Conclusions: Similar what has been observed a majority antibac-terial German decreased pandemic without rebound phenomenon In association restricted capacities presumably more immunocompromised general medi-cine patients, however, prescribing (primarily broad-spectrum) antibacterials increased.

Language: Английский